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Abstract
Background: The coronavirus disease 2019 (COVID-19) has become a pandemic health problem worldwide. In this study, we 
attempted to explain the clinical and laboratories characteristics of non-surviving patients, to identify the probable factors affecting 
disease progression.
Methods: In a retrospective study, we assessed the data from dead adult patients who were hospitalized and laboratory diagnosed 
with COVID-19 during March 2020. The data were obtained from electronic medical records. Moreover, a checklist including 
demographic, clinical, laboratorial, imaging, and treatment data was completed for each one of the patients. In case of lack of 
information, a member of the research team contacted the first-degree relatives via phone.
Results: Totally, 50 patients were enrolled in this study. The mean age was 68.0 ± 14.1 years. Of them, 29 (58%) patients were 
male. Notably, the median (IQR) hospitalization time was 4.0 (2.7–6.2) days and the duration between the first symptoms to 
death was 10.0 (5.0–14.5) days. Also, pre-existing morbidity was reported in 42 (84%) patients, and hypertension was the most 
common one with 28 (54%) patients. Interestingly, body temperature more than 37.5°C was reported in only 20 (40%) patients. 
Nevertheless, neutrophilia (≥7109/L) and lymphopenia (<1.0 109/L) were observed in 27 (54%) and 29 (58%) patients, respectively. 
Also, elevated levels of creatinine, lactate dehydrogenase (LDH), erythrocyte sedimentation rate (ESR), and C-reactive protein 
(CRP) were common, which may be indicators of aggravation of the patients’ status.
Conclusion: Besides age and underlying diseases, elevated creatinine level, neutrophil count, and the inflammatory indices along 
with the reduced lymphocyte count can be considered as indicators of disease progression. Hence, they should be considered for 
admission and surveillance of patients. 
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Introduction
A new RNA virus from the betacoronavirus family 
named severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) was first recognized in Wuhan, China, in 
December 2019. Since then, the virus has contaminated 
all parts of the world and become an endemic health 
problem.1 In the Middle East, the outbreak of coronavirus 
disease 2019 (COVID-19) was reported in Qom, Iran, in 
February 2020, for the first time. The virus was rapidly 
detected in the mass population in this city as well as 
other cities.  The city of Qom is located in the center of 
Iran with many industrial and religious centers and many 
daily visitors, resulting in many travels. The main route 
of transmission is person-to-person transmission in society 
and family settings; however, other routes of transmission 
need to be considered. Despite the fact that the virus mainly 
affects the respiratory system, other vital organ can also 
be affected seriously.2-4 Therefore, we can assume a wide 
spectrum of presentations in this situation. In fact, the 
common clinical presentations of COVID-19 are cough, 
dyspnea, fatigue, fever, chest pain, and myalgia. Moreover, 
alteration of complete blood count differential, and 
abnormal radiographic finding in chest CT scans are also 
reported.5-8 The mortality rate of COVID-19 is reported 
between 2% and 16% based on age.9 Furthermore, the 
rate of mortality may increase 2–10 folds among patients 
admitted to the intensive care unit (ICU) with preexisting 
morbidities such as cardiovascular diseases and diabetes.10 
In this regard, Chen et al reported that mortality in ICU 
admitted patients reached 4.3%. Accordingly, the main risk 
factors of mortality are advanced age, shortness of breath 
or dyspnea, low hemoglobin level, and having underlying 
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comorbidities.11 Li et al reported that the mortality rates 
for patients with hypertension, cerebrovascular diseases, 
and diabetes were two-, three-, and two-folds higher, 
respectively, in patients admitted to the ICU.12
The clinical characteristics of expired patients in our 
region has not been reported. In this study, we summarized 
the clinical features of expired cases with COVID-19 from 
Qom. The purpose of this study is to identify critically ill 
COVID-19 patients of early and to reduce their mortality.
Patients and Methods
Patients
In this retrospective study, we reviewed medical files of 
50 secondary non-surviving patients with COVID-19 
who were hospitalized in March 2020. The patients were 
admitted to Shahid Beheshti general hospital, which is 
the referral hospital for COVID-19 patients. All of them 
were laboratory diagnosed with COVID-19 based on the 
WHO guideline (detection of virus RNA was considered 
as confirmed positive result). Due to rapidity and the 
emergency situation, the data for all patients could be not 
completed; so, we selected the patients who had almost all 
the related data.
Data Collection
All data were obtained from the electronic file of each 
patient. Moreover, a checklist including demographic, 
clinical presentation, clinical assessment, and laboratories 
data was completed. In case of any lack of data, a member 
of the team contacted the first-degree relative of the patient. 
In the next step, data was entered into the computerized 
database. Afterward, two experienced clinicians reviewed 
the data. 
Laboratory Data
All activities, including sample collection and transfer, as 
well as lab safety issues were performed in compliance with 
the WHO guidelines for COVID-19 (WHO laboratory 
testing strategy recommendations for COVID-19: Interim 
guidance 2020). 
Venous blood samples, as the standard method, were 
then obtained on the first day of admission. Variables 
including the alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase (ALP), 
uric acid (UA), blood urea nitrogen (BUN), creatinine, 
and C-reactive protein (CRP) were analyzed using the 
diagnostic kits from Pars Azmoon Company (Pars Azmoon 
Co., Tehran, Iran) and Auto-Analyzer BS200 (Mindray, 
Shenzhen, China). 
Ethylene diamine tetra acetic acid (EDTA)-containing 
tubes were used for complete blood count (CBC) and 
differential blood counts using an automated blood 
cell counter (Sysmex K1000, Hamburg, Germany). 
For RNA extraction, a nasopharyngeal swab into viral 
transport media was used according to the manufacturer’s 
Table 1. Characteristics of Studied Patients
Variables
Total (n = 50)
No. (%)
Day of hospitalization, median (IQR) 4.0 (2.7–6.2)
Day from first symptom to admission, median (IQR) 5.0 (2.0–7.0)
Day from first symptom to death, median (IQR) 10.0 (5.0–14.5)
Age, mean ± SD (y) 68.0 ± 14.1
≥60 37 (74)
Gender (male) 29 (58)





Cardiovascular disease 15 (30)
Lung disease 7 (14)
Diabetes 14 (28)
Renal disease 8 (16)
Liver disease 1 (2)
Neurologic disease 9 (18)
Cancer 5 (10)
Use of immunosuppressive 2 (4)
instructions. Subsequently, a one-step real-time 
polymerase chain reaction (PCR) was performed by an 
assigned diagnostic laboratory, which was confirmed by 
the Ministry of Health based on universal protocols. All 
patients underwent a standard chest CT scan. Afterward, 
the results of the imaging were acquired via electronic 
reports for each patient. 
Statistical Analysis
Means (SD) and medians (IQR) were presented for 
normal and non-normal continuous variables, respectively. 
Normal distribution was checked using Shapiro-Wilk test 
and also normal probability plot (Q-Q plot). Categorical 
variables were expressed as number (%). All statistical 
analyses were performed using SPSS, version 20.0.
Results
In the present study, 50 expired patients with complete 
medical files were selected. Accordingly, the mean age 
was 68.0 ± 14.1 years. Of them, 29 (58%) subjects 
were male. The median length of hospitalization was 4 
(2.7–6.2) days and the median course of disease was 10 
(5–14.5) days.  Also, 42 (84%) of the patients had pre-
existing comorbidities, the most common of which 
were cardiovascular disease, hypertension, and diabetes, 
involving 15 (30%), 28 (56%), and 14 (28%) of patients, 
respectively. Smoking was found in 12 (24%) patients 
(Table 1). The majority of the patients had fever between 
37.5 and 38oC. Moreover, the most common complaints 
were shortness of breath in 44 (88%), fatigue/weakness 
in 32 (64%), and coughing in 32 (64%) patients. Quick 
SOFA score more than 2 was seen in 11 (22%) patients 
(Table 2).
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Table 3 illustrates the laboratory results on admission. 
White blood cell (WBC) count more than 10 ×109 was 
seen in 17 (34%) patients. Moreover, lymphopenia and 
neutrophilia were observed in 29 (58%) and 27 (54%) 
patients, respectively. An interesting finding was the 
hemoglobin (Hb) concentration which was >10 g/dL in 
the majority of the patients. The level of CRP ≥25 mg/L 
was also seen in 47 (98%) patients. In addition, lactate 
dehydrogenase (LDH) >500 U/L was reported in 34 (87%) 
patients. Elevated erythrocyte sedimentation rate (ESR) 
≥20 in 31(82%), SpO2 <90 mm Hg in 37 (74%), and 
international normalized ratio (INR) ≥1.3 in 21 (44%) 
patients were seen. Furthermore, elevated BUN ≥20 in 37 
(74%) patients and creatinine ≥1.3 in 35 (70%) patients 
were observed. Also, AST ≥40 and ALT ≥40 were reported 
in 33 (73%) and 15 (33%) patients, respectively. CT scan 
finding illustrated that all the patients had lung injuries. 
Moreover, all the patients had ground glass feature, in 
which consolidation was reported in 23 (46%) patients 
(Table 3).
Moreover, the most common complication was 
respiratory failure in 50 (100%) followed by acute 
respiratory distress syndrome (ARDS) in 49 (98%), acute 
kidney injury in 31 (62%), and acidosis in 24 (48%) 
patients (Table 4).
Discussion
This study presents one of the preliminary results 
regarding COVID-19 mortality in the city of Qom. This 
Table 2. Clinical Symptoms Among Studied Patients
Variables






Sore throat 22 (44)
Headache 7 (14)
Chest pain 21 (42)
Coughing 32 (64)





Shortness of breath 44 (88)
Dizziness 11 (22)
Nausea and vomiting 14 (28)
Abdominal pain 11 (22)
Diarrhea 12 (24)
Respiratory rate (≥24) 8 (16)
Pulse rate (≥120 ) 7 (14)
Quick SOFA (≥2 ) 11 (22)
Table 3. Laboratories Results Among Studied Patients
Variables (Normal Range)
Total (n = 50)
No.  (%)
WBC (4–9.5 ×109/L)













Mean ±SD 181.5 ± 65.0
>150000 36 (72)
100 000–150 000 10 (20)
<100 000 4 (8)
Hemoglobin (12–16 g/dL)
















Median (IQR) 1.4 (1.1 – 2.3)
<1.3 15 (30)
≥1.3 35 (70)
Total bilirubin (0.1–1.1 mg/dL)




Direct bilirubin (<0.4 mg/dL)
Median (IQR) 0.3 (0.2 – 0.4)
< 0.5 34 (77)
≥ 0.5 10 (22)
No checked 6
ALT (15–40 IU/L)
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city is known as the first site of COVID-19 detection in 
the Middle East. In this study, we observed that older age, 
male gender, and preexisting co-morbidities (particularly 
cardiovascular disease) are the most common risk factors. 
Almost all patient probably died secondary to respiratory 
failure and ARDS.
Generally, COVID-19 has characteristics similar 
to SARS-CoV-2.13 In the present study, the main 
ALP (98–279 U/L)









LAD (225–500 U/L) 



















Median (IQR) 7.4 (7.3 – 7.4)
<7.4 25 (53)
≥7.4 22 (47)
CO2 (36–44 mm Hg)











WBC, white blood cel; INR, international normalized ratio; BUN, blood urea 
nitrogen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; 
CRP, C-reactive protein; ALP, alkaline phosphataselactate; LDH, lactate 
dehydrogenase; ESR, erythrocyte sedimentation rate.
Variables (Normal Range)
Total (n = 50)
No.  (%)
Table 3. Continued Table 4. Complication Among Studied Patients
Variables
Total (n = 50)
No. (%)
Sepsis 18 (36)
Respiratory failure 50 (100)
ARDS 49 (98)
Septic shock 7 (14)
Coagulopathy based on INR >1.3 24 (48)
Acute kidney injury 31 (62)
Acidosis 24 (48)
ARDS, acute respiratory distress syndrome; 
complications were respiratory failure and ARDS 
followed by the kidney injuries. In fact, COVID-19 
can cause multi-organ damage.14-16 In previous reports, 
cardiovascular damage was considered at the top of the 
list of organ damage among COVID-19 patients.6,7,17 In 
the present study, the patients had not been evaluated 
regularly for cardiac events. Therefore, we cannot propose 
similar results in our patients. In fact, considering the 
common pre-existing cardiovascular problems as well as 
hypertension and diabetes among the patients, we suggest 
that cardiovascular events may be common factors that 
worsen the clinical situation of patients. A previous study 
indicated the association between cardiac events during 
pulmonary infection and following it.18,19 This mostly 
occurs in viral infections such as influenza.20,21 Notably, 
new cardiac events resulting from aggravation of preexisting 
cardiac problems were reported among patients with 
SARS.22 The mechanism of organ injuries in COVID-19 
is not elucidated yet. It is proposed that the virus can 
directly attack organs or it can accelerate the inflammatory 
mechanisms. Furthermore, cytokine storm remains as the 
main hypothesis in this regard.22,6 Moreover, in older age, 
the defense mechanism is not intact. There is also cytokine 
dysregulation causing defects in viral protection.23 Also, 
it has been observed that older age increases the odds of 
mortality. The reports from China and the United States 
suggest that age above 65 years significantly increases the 
risk of mortality. Explanations for this result may include 
the points that were mentioned above.24,25
Recent studies have indicated associations with CBC 
differential including lymphocyte and neutrophil levels 
as well as hemoglobin value.26-28 In fact, many studies 
show an association of lymphopenia with poor outcomes. 
Indeed, neutrophilia may be associated with acute cardiac 
events and sepsis development that can increase the odd 
of mortality. Also, studies regarding Hb value are more 
interesting because a decline in Hb level has been shown 
to be associated with poor outcome and mortality in 
previous reports.29 However, in the present study, our 
patients did not have low Hb values, which may be 
related to rapid progression of the disease and also the fact 
that we considered the Hb concentration on admission. 
Altogether, we suggest the assessment of CBC with 
 Arch Iran Med, Volume 23, Issue 12, December 2020                                                        868
Hormati et al 
differential on admission and during the follow-up period 
of patients. This simple test can help the physicians to 
predict the patients’ prognosis. Besides these findings, we 
must mention the elevated levels of CRP and LDH that 
are indicators of organ injuries and worsen the situation. 
Mardani et al indicated that values of LDH and CRP 
along with neutrophilia are associated with the presence 
of COVID-19.30 Li et al also emphasized the important 
role of LDH in prognosis of patients.31 Along with these 
laboratory data, we also need to rely on the results of 
CT scans as well the quick SOFA score. The presence 
of consolidation in CT assessment and qSOFA score 
more than 2 were also associated with increased odds of 
mortality in previous reports.25
In conclusion, the presence of underlying diseases along 
with older age by themselves may worsen the outcome of 
patients. COVID-19 is a complex disease that cause multi-
organ injuries. Therefore, simple alteration in laboratory 
value including Hb level, neutrophilia, and lymphopenia 
at the onset and during surveillance may provide a clue for 
poor prognosis. 
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